Selank: A Research Overview of the Anxiolytic Peptide
Developed in Moscow in the 1990s, Selank has remained largely unknown outside of specialized research circles. That's starting to change — and Canadian researchers are paying close attention.
The Peptide Developed Behind the Iron Curtain
In the 1990s, researchers at the Institute of Molecular Genetics in Moscow developed a synthetic heptapeptide with an unusual property: it appeared to reduce anxiety in preclinical models without producing sedation.
They called it Selank.
For decades, Selank remained largely confined to Russian and Eastern European research literature — studied extensively but not widely known in Western research circles. That is beginning to change, and Canadian researchers studying cognitive health, stress physiology, and anxiety biology are increasingly interested in what the literature says.
What Makes Selank Unique
Most compounds studied for anxiolytic effects share a common mechanism: they enhance GABA activity, the brain's primary inhibitory neurotransmitter. The problem is that enhancing GABA often produces sedation, cognitive impairment, and dependency — major limitations for research applications and therapeutic development.
Selank appears to modulate GABA differently. Preclinical research suggests it enhances GABAergic tone without the sedation profile of classical GABA-enhancing compounds. Researchers have also identified interactions with serotonin metabolism, dopaminergic pathways, and BDNF (Brain-Derived Neurotrophic Factor) expression.
This selectivity profile makes Selank a valuable research tool for investigators who want to study anxiolytic mechanisms without the confounding variables introduced by classical benzodiazepine-like compounds.
The BDNF Connection
BDNF is a neurotrophin that supports the growth, maintenance, and differentiation of neurons. It has been extensively studied in the context of depression, anxiety, cognitive function, and neuroplasticity. Research has suggested that reduced BDNF expression is associated with stress-related disorders in animal models.
Selank has been shown in preclinical studies to upregulate BDNF expression in several brain regions. This effect is separate from its anxiolytic properties and represents a distinct research angle — particularly for investigators exploring the relationship between stress, BDNF, and cognitive performance.
Nasal Spray Delivery for CNS Research
The intranasal delivery route offers particular advantages for compounds that interact with central nervous system receptors. The olfactory pathway provides direct anatomical access to brain tissue, bypassing the blood-brain barrier and hepatic metabolism.
For Selank research specifically — where CNS receptor interactions are the primary area of interest — the nasal spray format aligns with the delivery route most commonly used in the published literature.
Popular Peptides Selank Nasal Spray
Popular Peptides supplies Selank Nasal Spray (10ml) as a research-grade compound for Canadian investigators. ≥99% purity, independently third-party tested, Certificate of Analysis included.
**Disclaimer**: For laboratory and research use only. Not approved by Health Canada for therapeutic use.